A study which assessed the effect of Env gp120 vaccination in the VAX004 trial on the subsequent neutralizing antibody responses to HIV-1 infection found no significant differences between HIV-infected vaccinated and placebo recipients (2). This evidence concerns the gene ITIH4 and HIV-1 infection.